Transgenic mice overexpressing human GFAP (AxD-like features reduced); species surrogate ASO in rat AxD model
“Specifically, administration of zilganersen reduced GFAP mRNA and AxD-like features in transgenic mice overexpressing human GFAP; additionally, a species surrogate ASO reduced brain GFAP mRNA and decreased GFAP protein in the CSF of a rat model of AxD.”
FDA: target engagement and mechanistic data confirmed biologic plausibility of the treatment benefit
“These target engagement and mechanistic data confirmed the biologic plausibility of the observed treatment benefit and that the drug is having its intended effect.”